ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1589

Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis

Kristina Clark1, Corrado Campochiaro2, Philip Yee3, Emma Derrett-Smith4, Voon Ong5 and Christopher Denton6, 1University of Oxford, Oxford, United Kingdom, 2IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, 3UCL, London, United Kingdom, 4University College London Division of Medicine, Birmingham, United Kingdom, 5University College London, London, England, United Kingdom, 6University College London, Northwood, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), Genomics and Proteomics, Scleroderma, skin, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement.  We have asked whether whole skin gene expression may explain these differences.

Methods: Genome-wide bulk RNA sequencing was performed on SSc patients with specific antibodies were included (anti-RNApol III (ARA) (n=6), anti-topoisomerase (ATA) (n=6) and anticentromere (ACA) (n=9)) as well as healthy controls (n=16). Analysis was carried out in Rstudio. Corrected t-test, and ANOVA tests were used for multiple group comparison. Significance for paired comparisons was ≥1.5-fold change with adjusted p-value < 0.05. For ANOVA comparisons, p value of < 0.05, and adjusted p-value of < 0.3 was considered significant. Gene set enrichment was obtained using gProfiler.

Results: Principal component analysis (PCA) analysis separated autoantibody subgroups (Fig 1). There were 288 significantly differentially expressed genes between SSc and HC, of which 231 were significantly elevated in SSc, including COMP (FC 3.71), SFRP4 (FC 2.64), THBS4 (Log FC 2.66). Pathway analysis revealed significant over expression of extracellular matrix (ECM) pathways, immune response activation, and regulation of complement cascade.

391 genes were significantly differentially expressed between ARA+, ATA+ and ACA+. Unsupervised hierarchical clustering grouped patients by antibody (Fig 2). Four gene expression modules separated ANA subgroups. Module 1 was overexpressed in all dcSSc compared with ACA+ patients. These included COL3A1, WNT2, ADAMTS12, and gene set enrichment revealed predominantly pathways associated with ECM, collagen fibril organization and adaptive immune response. Module 2 was upregulated in ARA+ patients but downregulated in ATA+ and ACA+ patients. This included genes MS4A1, CXCL13, CXCL8. Module 3 was downregulated in ARA+ and upregulated in ATA+ and ACA+ patients. This subgroup included HOTAIR, MYO10, SERPINB9P1. Module 4 was upregulated in ACA+ but downregulated in ARA+ and ATA+. These genes included WIF1, FGFBP1, SPAC17, and CADM3, with upregulation of heparin binding pathway, tissue development and multicellular organismal process.

Conclusion: There were notable differences based on autoantibody not appreciated by disease subset. The absence of cardiovascular genes modules differentiated autoantibody subgroups in consistent with a unifying vasculopathy signature across disease subtypes.

Supporting image 1

PCA showing clustering aby autoantibody (ACA, ARA, ATA and Healthy control (HC))

Supporting image 2

Unsupervised heirarchical clustering of gene expression by autoantibody. 4 modules were identified.


Disclosures: K. Clark: None; C. Campochiaro: Boehringer-Ingelheim, 1, 6, Janssen, 6, Novartis, 1, 6; P. Yee: None; E. Derrett-Smith: None; V. Ong: None; C. Denton: AbbVie, 2, 5, Acceleron, 2, Arxx Therapeutics, 2, 5, Bayer, 2, Boehringer Ingelheim, 2, 6, Certa, 2, Corbus, 2, CSL Behring, 2, 5, Galapagos, 2, GlaxoSmithKline, 2, 5, 6, Horizon, 2, 5, Inventiva, 2, Janssen, 2, 6, Lilly, 2, Novartis, 2, Roche, 2, Sanofi-Aventis, 2, Servier, 5, Zurabio, 2.

To cite this abstract in AMA style:

Clark K, Campochiaro C, Yee P, Derrett-Smith E, Ong V, Denton C. Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/whole-skin-gene-expression-analysis-identifies-discrete-modules-that-differentiate-antinuclear-antibody-subsets-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-skin-gene-expression-analysis-identifies-discrete-modules-that-differentiate-antinuclear-antibody-subsets-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology